Acupuncture reduces crying in infants with infantile colic: a randomised, controlled, blind clinical study Kajsa Landgren, Nina Kvorning and Inger Hallström Acupunct Med doi: 10.1136/aim.2010.002394Updated information and services can be found at: References This article cites 52 articles, 10 of which can be accessed free at: Open Access This paper is freely available online under
Suomen sivusto, jossa voit ostaa halvalla ja laadukas Viagra http://osta-apteekki.com/ toimitus kaikkialle maailmaan.
Erityisesti laatu viagra tästä kaupasta voi taata henkilökohtaisesti kamagra Paras laatu kehotan Teitä miellyttää.
Pr 2-04-07BurnsAdler Pharmaceuticals, Inc. enters into an Exclusive Licensing
Agreement with Nephron Pharmaceuticals to commercialize S2®
Racepinephrine and Ipratropium Bromide and Albuterol Sulfate in Mexico
Charlotte, NC (August 27, 2012) – BurnsAdler Pharmaceuticals, Inc. (“BurnsAdler”), a portfolio company
of Bourne Partners, a healthcare focused merchant bank and private equity firm, announced today that it has entered into an exclusive long-term licensing and supply agreement with Nephron Pharmaceuticals Corporation (“Nephron”) to market S2® Racepinephrine Inhalation Solution USP, 2.25% and Ipratropium Bromide and Albuterol Sulfate (Duo Dose) Inhalation Solution (0.5mg-3mg/3ml) in Mexico. Banks Bourne, Chairman of BurnsAdler remarked, “Nephron Pharmaceuticals is an innovative and growing organization and we are very pleased to enter into this long-term partnership. S2® and Ipratropium Bromide and Albuterol Sulfate will be important options for patients suffering from respiratory diseases in Mexico. This agreement continues BurnsAdler’s tradition of bringing quality medications to markets in Latin America.” S2® Racepinephrine is a proven, FDA-approved medication, indicated for the temporary relief of shortness of breath, tightness of chest, and wheezing due to bronchial asthma. The fast-acting solution is inhaled by the patient using an easy-to-use atomizer or nebulizer. Ipratropium Bromide and Albulterol Sulfate helps to relieve bronchospasm in patients 12 years of age or older with reversible obstructive airway disease and acute attacks Lou Kennedy, CEO of Nephron Pharmaceuticals commented, “This relationship marks an important step in Nephron’s plans to commercialize our products internationally. We trust that a strong and experienced partner, like BurnsAdler will allow us to maximize the potential of the S2® and Ipratropium Bromide and Albuterol Sulfate product lines in Mexico.” BurnsAdler is fully-owned portfolio company of Bourne Partners.
About BurnsAdler Pharmaceuticals, Inc.
BurnsAdler Pharmaceuticals, Inc. is a specialty pharmaceutical company that commercializes products throughout Latin America. Through relationships with product developers from the Unites States and Europe, BurnsAdler offers a turn-key solution to help deliver world-class medicine to these challenging international markets. BurnsAdler’s portfolio includes pharmaceutical products and medical devices used in oncology, gastroenterology, cardiovascular medicine, orthopedics, emergency medicine and other critical care settings.
About Nephron Pharmaceuticals
Nephron Pharmaceuticals Corp. is a private, woman owned manufacturer of generic inhalation solutions,
headquartered in Orlando, Florida, and employs 500 persons nationwide. Nephron has manufactured billions of doses of life saving medications since 1997. The company is developing a new facility in Cayce, South Carolina, which will expand its product line to include ophthalmic and injectable medications, and provide About Bourne Partners
Headquartered in Charlotte, North Carolina, Bourne Partners is a healthcare-focused merchant banking firm that provides advisory services and capital to companies throughout the world. The firm specializes in domestic and cross border advisory assignments with primary concentration in healthcare. Advisory areas of focus include corporate partnering (joint venture/licensing), mergers and acquisitions, and financing services. Bourne Capital Partners invests in top tier private equity funds, co-invests with those funds and makes direct investments in companies with compelling return characteristics. The firm’s principals have completed in excess of $2 billion in healthcare transactions globally. For additional information, visit www.bourne- For additional information about this news release, please contact Jeremy Johnson at (704) 714-8351 . For additional information about Bourne Partners, please refer to the company’s website at
De D n e t n a t l a lR e R g e i g s i t s r t a r t a i t o i n o n a n a d n d H i H s i t s o t r o y r 1 Patient Information 2 Dental Insurance Who is responsible for this account? __________________________Date ___________